What's hot
View all perspectives
Dr. John Cush RheumNow
9 months 3 weeks ago
RheumNow Day 2 Recap: ACR Convergence 2024 Highlights https://t.co/YAwOEaNsWs
Dr. John Cush RheumNow
9 months 3 weeks ago
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty
Brian Jaros, MD Dr_Brian_MD
9 months 3 weeks ago
We saw evidence for JAK use in GCA this conference... what about IL-1 inhibition?
Double-blind RCT: Anakinra vs. PBO w/ similar GC taper in GCA pt
NO difference in relapse rate at 26, 52 wks despite addition of Anakinra
@RheumNow #ACR24 Abst1699 https://t.co/gUb0gGJjTG
Brian Jaros, MD Dr_Brian_MD
9 months 3 weeks ago
VERY exciting SLE update from Fava et al. Machine learning used to generate urinary protein panel predictive of intra-renal inflammation BETTER than serum biomarkers C3, C4, dsDNA Also monitoring tool for renal response. Outstanding. @RheumNow #ACRbest #ACR24 https://t.co/YXgKrSU4UQ
Janet Pope Janetbirdope
9 months 3 weeks ago
To stop tsDMARD / bDMARD To improve #COVIDVACCINE response in those w several previous #COVID19 #vaccinations is NOT necessary
This will change my practice!
#ACR24 @RheumNow @ACRheum https://t.co/WXeqMOEfuA
Brian Jaros, MD Dr_Brian_MD
9 months 3 weeks ago
What a result!!!
Crowed split 49% against and 51% for MCTD as a unique disease entity
Given pre-debate poll of >70% for MCTD, looks like an overall win for the “NOT” group
Fantastic session from all the presenters
@RheumNow #ACR24 https://t.co/GgTVQ1VNWP
Mike Putman EBRheum
9 months 3 weeks ago
Super helpful results from COVER study, holding JAK or IL17 for COVID boosters Antibody titers went up regardless of holding Holding caused flares (14-25% increase!) Pretty clear message; continue JAK / IL17 #ACR24 @RheumNow Abstr#1718 #ACRbest https://t.co/Mf89dWrRWz
Brian Jaros, MD Dr_Brian_MD
9 months 3 weeks ago
Would be helpful for us (and pts) to better understand rimmunotherapy agent specific risk on subsequent GCA/PMR
AFTRER propensity matching of >7k pt on combo nivolumab/ipilimumab compared to pembrolizumab:
- PMR RR 3.8x N/I vs. P
- no diff in GCA risk
@RheumNow #ACR24 https://t.co/IF4Gh7Cumd
Mithu Maheswaranathan, MD MithuRheum
9 months 3 weeks ago
🔶Clinical Year in Review #ACR24 🔶
Talk By @MHPillingerMD
• Review some of the most impactful studies in Rheumatology from the past year!
#RheumTwitter #Rheumatology https://t.co/1ULDB2l4gX
Brian Jaros, MD Dr_Brian_MD
9 months 3 weeks ago
The anti-MCTD group strikes back
Of cohort of over 1,000 RNP+ pt, only 17 clinically diagnosed with MCTD
Majority of patients, despite potential overlap, treated for other primary rheum dz
@RheumNow #ACR24 https://t.co/vkQ6UPs34y
Jiha Lee JihaRheum
9 months 3 weeks ago
Older RA patients in RISE with high disease activity show a higher incidence of hip and major osteoporotic fractures. Practice T2T and monitor bone health closely!
#ACR24 @RheumNow ABST#1748 https://t.co/7MCAIrfXhp
Adela Castro AdelaCastro222
9 months 3 weeks ago
Phase 2 RCT of MK2 inhibitor did not show clinical efficacy at week 12 in active AS pts compared to PBO.
There are still unmet needs for additional therapeutics in pts with AS that not respond to current therapies.
Abst#1760 #ACR24 @RheumNow https://t.co/cXv8HYr0Xr
Abstract 1731 is a small RCT of baricitinib in inflammatory myositis comparing early start baricitinib to later start.
Mrinalini Dey DrMiniDey
9 months 3 weeks ago
Comparison of infection risk across b/tsDMARDs in IA in real-world study
Treatment with
➡️Rituximab
➡️JAKi
➡️Anti-IL6
assoc with ⬆️⬆️ risk of severe infection compared to TNFi
A reminder to consider comorbidities & infection risk in selecting b/tsDMARDs
Ab1716 #ACR24 @RheumNow
Poster Hall